Proactive Investors - Run By Investors For Investors

Silence Therapeutics accelerating into the clinic

David Solomon, chief executive of Silence Therapeutics PLC (LON:SLN), updates Proactive London's Andrew Scott on the progress of its lead candidate SLN124  which is being developed to treat iron overload disorders.

It already has orphan drug designation in Europe and a phase Ib, first-in-human trial is scheduled to start in the third quarter.

Solomon also elaborates on two other exciting assets in the portfolio - one of them being SLN360 which is being developed as a potential treatment for cardiovascular disease.

 
Meet Faron Pharmaceuticals Ltd, Belvoir Lettings, Silence Therapeutics PLC, ANGLE PLC and ReNeuron Group PLC at our event, London , 23 May 2019. Register here »
View full SLN profile View Profile

Silence Therapeutics PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use